Clinical trials: Hypertrophy, Left Ventricular
Hypertensive Left Ventricular Hypertrophy
Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy
The primary objective of this study is to determine which treatment will be more effective to reduce left ventricular mass in hypertensive patients with left ventricular hypertrophy comparing aliskiren and eplerenone.
- Trial name
- EARTH (NCT01893788)
- Testing
- Aliskiren, Eplerenone
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Nagoya University
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
This study aims to evaluate whether, under a treatment strategy primarily guided by left ventricular ejection fraction (LVEF), dose up-titration in adult patients with symptomatic obstructive hypertrophic cardiomyopathy who have…
- Trial name
- NCT07807384
- Testing
- Mavacamten
- Volunteers
- 115 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Hypertrophic Cardiomyopathy (HCM), Obstructive Hypertrophic Cardiomyopathy (oHCM)
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
This retrospective cohort study aims to evaluate the clinical efficacy and safety of mavacamten in adult patients with obstructive hypertrophic cardiomyopathy (oHCM).
- Trial name
- MAVA-HCM (NCT07529938)
- Testing
- mavacamten
- Where
- China
- Volunteers
- 222 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Cardiac Amyloidosis
Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
Tne aim purpose of this observational, multicentre and propective study is to determine the prevalence of cardiac amyloidosis in geriatric patients aged 80 years and older hospitalized within the last 12 months for heart failure…
- Trial name
- ARNOLD (NCT06427304)
- Where
- 36 sites in France
- Volunteers
- 637 people
- Sponsor
- Gérond'if
Hypertension, Left Ventricular Hypertrophy
Effect of Valsartan on Left Ventricular Myocardial Functions in Hypertensive Patients With Left Ventricular Hypertrophy
The study hypothesis: Valsartan as an angiotensin II receptor blocker treatment has beneficial effects on both midwall mechanics and myocardial functions in hypertensive patients with Left ventricular hypertrophy.
- Trial name
- NCT01425411
- Testing
- valsartan
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people
- Sponsor
- Mustafa Kemal University
Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy
Image-Based Prediction of Ventricular Tachycardia Events in Non-ischemic Cardiomyopathy
Risk stratification for sudden cardiac death (SCD) in patients with non-ischemic cardiomyopathy (NICM) remains suboptimal. Although current guidelines rely on severe left ventricular systolic dysfunction (left ventricular…
- Conditions
- Dilated Cardiomyopathy, Arrhythmogenic Cardiomyopathy, Ventricular Arrhythmia, Hypertrophic Cardiomyopathies
- Trial name
- IMPROVE-NICM (NCT06730464)
- Where
- 4 sites in Italy, Portugal and 1 more
- Volunteers
- 500 people
- Sponsor
- Centro Medico Teknon
Hypertrophic Cardiomyopathy, Obstruction
4D-flow MRI to Assess Left Ventricular Obstruction in Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a frequent cardiac pathology with an estimated prevalence of 1/500 in France. The main risk factor for sudden death in this pathology is the presence and extent of left ventricular…
- Conditions
- Hypertrophic Cardiomyopathy, Obstruction, Echocardiography
- Trial name
- CMHFLUX (NCT04439942)
- Testing
- cardiac magnetic resonance imaging (MRI)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Left Ventricular Hypertrophy
Demographical and Clinical Profile of Patients With Left Ventricular Hypertrophy
Left ventricular hypertrophy (LVH) is the most common result of the heart trying to pump blood against the high afterload, as in hypertension and aortic stenosis.Although hypertension is the most common cause of LVH, LVH can also…
- Trial name
- NCT04275882
- Testing
- Electrocardiogram
- Where
- Turkey (Türkiye)
- Volunteers
- 886 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited
Cardiac Rehabilitation
"Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy".
Hypertrophic cardiomyopathy (HCM) is the most common hereditary disease characterized by left ventricular hypertrophy and consequently left ventricular diastolic dysfunction.
- Trial name
- NCT03178357
- Testing
- Cardiac rehabilitation + standard therapy, Standard therapy
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- National Institute of Cardiology, Warsaw, Poland
Masked Hypertension
Antihypertensive Treatment in Masked Hypertension
The primary purpose of the study is to estimate the target organ protection after 12 months of antihypertensive treatment in masked hypertension patients with at least one kind of target organ damage (left ventricular…
- Trial name
- ANTI-MASK (NCT02893358)
- Testing
- Allisartan Isoproxil
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Yan Li
Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy
NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study
Background: Some people have a condition in which the wall (septum) that separates the two main pumping chambers of the heart is too thick.
- Conditions
- Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
- Trial name
- NCT06269640
- Testing
- Septal Scoring Along Midline Endocardium
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Fabry Disease
Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy
The purpose of this study was to assess the progression of cardiac involvement in adult patients with Fabry Disease (FD), in the unique Danish Fabry cohort and comparing those FD patients receiving primary therapy vs.
- Trial name
- NCT02908724
- Volunteers
- 66 people
- Sponsor
- Ulla Feldt-Rasmussen
Hypertension, Arteriosclerosis
The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients
Unfavorably high sodium intakes remain prevalent around the world. A negative sodium gradient in hemodialysis treatment results in absolute sodium removal via diffusive transport of sodium from the blood to the dialysate, and it…
- Conditions
- Hypertension, Arteriosclerosis, Left Ventricular Hypertrophy
- Trial name
- NCT01455974
- Testing
- Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Capital Medical University
Kidney Disease, Left Ventricular Hypertrophy
Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
Cardiovascular related disease is the main cause of death in patients with kidney disease, and "oxidative stress" is thought to be a major contributor by promoting thickening of the heart muscle and stiffening of the arteries.
- Trial name
- NCT00688480
- Testing
- Allopurinol
- Where
- United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- A. D. Struthers
Cardiovascular Diseases, Heart Diseases
Racial Differences in the Coronary Microcirculation
To study mechanisms of excess coronary ischemia secondary to alterations in autoregulation and arteriolar vasoreactivity in Black Americans with hypertension, varying degree of left ventricular hypertrophy, and angiographically…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Hypertension
- Trial name
- NCT00005373
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypertension
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)
Evaluate pleiotropic effects of simvastatin in hypertensive patients.
- Trial name
- NCT00738972
- Testing
- valsartan, pravastatin, simvastatin
- Volunteers
- 12 people
- Sponsor
- Fundación Lindavista del Corazón AC
Long QT Syndrome, Sinus Bradycardia
A Study to Evaluate Accuracy and Validity of the Chang Gung ECG Abnormality Detection Software
"Chang Gung ECG Abnormality Detection Software" is a is an artificial intelligence medical signal analysis software that detect whether patients have abnormal ECG signals of 14 diseases by static 12-lead ECG.
- Conditions
- Long QT Syndrome, Sinus Bradycardia, Sinus Tachycardia, Premature Atrial Complexes
- Trial name
- NCT05903313
- Testing
- Chang Gung ECG Abnormality Detection Software
- Where
- Taiwan
- Volunteers
- 4,306 people
- Sponsor
- Chang Gung Memorial Hospital
Fabry Disease, Fabry Disease, Cardiac Variant
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years.
- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases, HCM - Hypertrophic Cardiomyopathy
- Trial name
- FAPREV-HCM (NCT04943991)
- Testing
- blood sampling (alpha-Galactosidase & LysoGb3)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
HFpEF, LVDD
Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF
Patients with advanced heart failure with preserved ejection fraction (HFpEF) will be randomly assigned in open-label multicenter study to receive triple combination therapy with [angiotensin receptor/neprilysin inhibitor [ARNI]…
- Conditions
- HFpEF, LVDD, Myocardial Fibrosis
- Trial name
- NCT06655480
- Testing
- [ARNI + SGLTi + AMR], [SGLTi + previously taken RAAS blocker]
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation